^
    Back
    Association details:
    Biomarker:ABL1 T315I
    Cancer:Acute Lymphocytic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    J Med Case Rep
    Title:

    Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports

    Published date:
    03/25/2021
    Excerpt:
    A 69-year-old Japanese male with R/R Ph+ ALL was treated with conventional chemotherapy and dasatinib in April 2016. In May 2018, he developed molecular relapse due to the acquisition of T315I during dasatinib maintenance therapy.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1186/s13256-021-02771-z